#Clinical Trials — FinScans

News 📈 Stocks

Cue Biopharma Shares Surge 41.6% on Positive Phase 2 Clinical Trial Results

September 21, 2026 (33 days ago)

Cue Biopharma stock jumped 41.6% as positive Phase 2 data for its urticaria treatment CUE-221 met key clinical endpoints, signaling a potential…

CUE

🌍 AMERICAS Read More →

News 📈 Stocks

Merck Shares Rally 87% as Pipeline Progress Outpaces Revenue Growth

September 20, 2026 (34 days ago)

Merck's 87% stock gain reflects investor confidence in its clinical pipeline and new product launches, even as revenue growth shows signs of…

MRK JNJ PFE

🌍 US Read More →

Earnings 📈 Stocks

Innate Pharma Extends Cash Runway to 2028 Following $75M Sobi Partnership

September 19, 2026 (35 days ago)

Innate Pharma strengthens its balance sheet with a $75M Sobi payment and $30M equity raise, supporting a robust clinical pipeline that includes…

IPHA SOBI

🌍 EUROPE Read More →

News 📈 Stocks

Novartis Shares Plunge 11% After $32 Billion Market Value Wipeout

September 19, 2026 (35 days ago)

Novartis stock plummeted 10.9% following the failure of its del-desiran trial, triggering a sector-wide selloff in muscular-disease stocks including Sarepta and Dyne…

NVS SRPT DYN

🌍 EUROPE Read More →

News 🌐 Macro — 📊 Neutral

BlossomHill Therapeutics Shares Rally 4.4% on Positive Lung Cancer Trial Data

September 17, 2026 (38 days ago)

BlossomHill Therapeutics stock gains 4.4% as the company reports a 45% objective response rate for its BH-30643 lung cancer treatment in the…

ORIC Pharmaceuticals Launches Phase 3 Prostate Cancer Trial With $387M Runway

September 15, 2026 (39 days ago)

ORIC Pharmaceuticals advances its clinical pipeline with a new Phase 3 prostate cancer trial, balancing a robust cash runway against significant share…

ORIC BAYN

🌍 AMERICAS Read More →

News 📈 Stocks

Definium Therapeutics Shares Rally 190% YTD on Positive Phase 2 LSD Trial Data

September 14, 2026 (40 days ago)

Definium Therapeutics shares climb as synthetic LSD treatment shows superior efficacy in Phase 2 anxiety trials, marking another milestone for the biotech…

DFTX

🌍 AMERICAS Read More →

News 📈 Stocks

Olema Shares Slide 15% as AstraZeneca Breast Cancer Trial Fails

September 14, 2026 (40 days ago)

Olema Pharmaceuticals shares fell 15.1% after AstraZeneca's camizestrant failed a key breast cancer trial, prompting Stifel to cut its price target on…

OLMA AZN

🌍 AMERICAS Read More →

News 📈 Stocks

Novartis Pelacarsen Trial Failure Triggers 10% Amgen Sell-Off

September 14, 2026 (40 days ago)

Novartis' failed cardiovascular trial for pelacarsen has roiled the biotech sector, causing a 10% drop in Amgen shares while Eli Lilly maintains…

NVS AMGN IONS +1

🌍 AMERICAS Read More →

News 📈 Stocks

Royalty Pharma Limits Losses After Novartis Pelacarsen Phase 3 Trial Failure

September 12, 2026 (42 days ago)

Royalty Pharma pivots to Spinraza royalties to recoup its $500 million investment after the Phase 3 failure of Novartis's cardiovascular drug, pelacarsen.

RPRX IONS NVS

🌍 AMERICAS Read More →

News 📈 Stocks

Novartis Shares Slump 13% on Failed Clinical Trial, Amgen Drops 9%

September 10, 2026 (45 days ago)

Novartis shares plummeted 13% following a failed clinical trial for del-desiran, while Amgen shares dropped 9% on contagion fears, pressuring the Dow…

AMGN DJIA

🌍 NORTH AMER Read More →

News 📈 Stocks — 📉 Bearish

Novartis Shares Plunge 12% Following Dual Phase 3 Clinical Trial Failures

September 9, 2026 (45 days ago)

Novartis shares fell 12.57% following two major clinical trial disappointments, triggering a broader sell-off in biotech partners Ionis Pharmaceuticals and Royalty Pharma.

🌍 NORTH AMER Read More →